ISRCTN35754083已完成不适用
Phase II, double blind, randomised, controlled study to evaluate immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals Hib-menAC vaccine (Ghana)
GlaxoSmithKline (GSK) Biologicals (Ancillary study - Swiss Tropical Institute) (Belgium)0 个研究点目标入组 280 人开始时间: 2004年9月22日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 280
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Healthy infants between 6 - 8 weeks of age at first vaccination.
排除标准
- •Any condition that may affect the health of the subject, or the interpretation of the results.
研究者
相似试验
进行中（未招募）
不适用
A clinical study to evaluate the efficacy to stop the bleeding and safety of TT-173 applied in the donor site of patients undergoing skin graft.EUCTR2013-002784-25-ESThrombotargets Europe
已完成
不适用
Phase II multi-centre study to evaluate efficacy, safety, and immunogenicity of GMZ2 candidate malaria vaccine in children aged 12 to 60 monthsPaediatricsMalariaPACTR2010060002033537Statens Serum Intitute1,840
已完成
2 期
A phase II study of the Cuban adult formulation tetanus and diphtheria vaccine.Tetanustetanus and diphtheriaClostridium InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsCorynebacterium InfectionsActinomycetales InfectionsDiphtheriaRPCEC00000059Finlay Institute225
已完成
2 期
A phase II study of the Cuban vaccine against tetanus and diphtheria VA-DIFTET.tetanus and diphtheriaClostridium InfectionsGram-Positive Bacterial InfectionsBacterial InfectionsCorynebacterium InfectionsActinomycetales InfectionsTetanusDiphtheriaRPCEC00000058Finlay Institute300
进行中（未招募）
不适用
A phase II, randomized, double-blind, controlled study to evaluate the immune responses, safety and clinical efficacy of three doses of Neovacs’ TNF-Kinoid in adult patients with rheumatoid arthritis who have relapsed despite anti-TNFa biological therapyMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2009-012041-35-BEeovacs SA48